WO2003039523A3 - Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha - Google Patents

Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha Download PDF

Info

Publication number
WO2003039523A3
WO2003039523A3 PCT/IB2002/005080 IB0205080W WO03039523A3 WO 2003039523 A3 WO2003039523 A3 WO 2003039523A3 IB 0205080 W IB0205080 W IB 0205080W WO 03039523 A3 WO03039523 A3 WO 03039523A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel
rna
oligonucleotides modified
rna analogues
relates
Prior art date
Application number
PCT/IB2002/005080
Other languages
English (en)
Other versions
WO2003039523A2 (fr
Inventor
Jesper Wengel
Original Assignee
Exiqon As
Jesper Wengel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exiqon As, Jesper Wengel filed Critical Exiqon As
Priority to AU2002351077A priority Critical patent/AU2002351077A1/en
Publication of WO2003039523A2 publication Critical patent/WO2003039523A2/fr
Publication of WO2003039523A3 publication Critical patent/WO2003039523A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/337—Chemical structure of the base in alpha-anomeric form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)

Abstract

La présente invention concerne de nouveaux monomères d'ARN-L-α, qui, lorsqu'ils sont incorporés dans un oligonucléotide altèrent une tendance plus élevée à l'hybridation avec un complément d'ARN, comparé à un complément d'ADN. L'invention concerne également un procédé de préparation d'un oligonucléotide modifié d'ARN-L-α et un intermédiaire permettant sa fabrication. Lesdits nouveaux oligonucléotides sont utiles dans une variété d'applications thérapeutiques, diagnostiques et de biologie moléculaire générales.
PCT/IB2002/005080 2001-11-05 2002-11-05 Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha WO2003039523A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002351077A AU2002351077A1 (en) 2001-11-05 2002-11-05 Oligonucleotides modified with novel alpha-l-rna analogues

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33744701P 2001-11-05 2001-11-05
DKPA200101640 2001-11-05
US60/337,447 2001-11-05
DKPA200101640 2001-11-05

Publications (2)

Publication Number Publication Date
WO2003039523A2 WO2003039523A2 (fr) 2003-05-15
WO2003039523A3 true WO2003039523A3 (fr) 2003-12-04

Family

ID=29585604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/005080 WO2003039523A2 (fr) 2001-11-05 2002-11-05 Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha

Country Status (2)

Country Link
AU (1) AU2002351077A1 (fr)
WO (1) WO2003039523A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
WO2004113563A2 (fr) * 2003-06-20 2004-12-29 Exiqon A/S Sondes, bibliotheques et trousses d'analyse pour melanges d'acides nucleiques et methodes de realisation
DK1639130T3 (da) 2003-06-20 2012-07-09 Exiqon As Prober, biblioteker og kits til analyse af blandinger af nukleinsyrer og metoder til opbygning af disse
CA2577526A1 (fr) 2004-08-23 2006-03-02 Joseph Armstrong Martin 4'-azido-nucleosides antiviraux
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
AP2009004812A0 (en) 2006-10-10 2009-04-30 Medivir Ab HCV nucleoside inhibitor
WO2007054100A2 (fr) * 2006-11-13 2007-05-18 Santaris Pharma A/S Phosphoramidates du nucléoside lna
EP2231168A4 (fr) 2007-10-03 2012-01-04 Quark Pharmaceuticals Inc Nouvelles structures d'arnsi
EP2229457A4 (fr) 2007-12-14 2011-01-26 Minitube America Inc Séparation spécifique à chaque sexe de spermatozoïdes et d'embryons
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
KR20110128947A (ko) 2009-03-20 2011-11-30 앨리오스 바이오파마 인크. 치환된 뉴클레오시드 및 뉴클레오티드 유사체
WO2011032034A2 (fr) 2009-09-10 2011-03-17 University Of Idaho Nucléotides et oligonucléotides à conformation restreinte à fonctionnalité nucléobase pour cibler des acides nucléiques
WO2012037531A1 (fr) * 2010-09-16 2012-03-22 Gen-Probe Incorporated Sondes de capture immobilisables par l'intermédiaire d'une queue nucléotidique l
PE20140608A1 (es) 2010-09-22 2014-06-12 Alios Biopharma Inc Analogos de nucleotidos sustituidos
WO2012040124A1 (fr) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Azido nucléosides et analogues nucléotidiques
WO2012135805A2 (fr) 2011-03-31 2012-10-04 modeRNA Therapeutics Administration et formulation d'acides nucléiques génétiquement modifiés
RU2014106024A (ru) 2011-07-19 2015-08-27 Юниверсити Оф Айдахо Варианты осуществления зонда и способы направленного действия на нуклеиновые кислоты
PL2794627T3 (pl) 2011-12-22 2019-04-30 Alios Biopharma Inc Podstawione nukleozydy, nukleotydy i ich analogi
EP2794630A4 (fr) 2011-12-22 2015-04-01 Alios Biopharma Inc Analogues de nucléotide phosphorothioate substitués
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2013142157A1 (fr) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
UY34824A (es) 2012-05-25 2013-11-29 Janssen R & D Ireland Nucleósidos de espirooxetano de uracilo
WO2014033617A1 (fr) 2012-08-31 2014-03-06 Novartis Ag Dérivés de 2'-éthynyle nucléoside de traitement d'infections virales
KR102327888B1 (ko) 2012-12-21 2021-11-17 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체
WO2014100934A1 (fr) * 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Inhibiteurs de glycosidases et leurs utilisations
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
WO2014152027A1 (fr) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Procédés de fabrication pour la production de transcrits d'arn
WO2014144767A1 (fr) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Purification d'arnm par échange d'ions
WO2014152030A1 (fr) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Elimination de fragments d'adn dans des procédés de production d'arnm
EP3971287A1 (fr) 2013-07-11 2022-03-23 ModernaTX, Inc. Compositions comprenant des polynucléotides synthétiques codant pour des protéines liées à crispr et des arnsg synthétiques et méthodes d'utilisation
WO2015051169A2 (fr) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Molécules de polynucléotides et leurs utilisations
SG10201804835VA (en) 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
EP3157573A4 (fr) 2014-06-19 2018-02-21 Moderna Therapeutics, Inc. Molécules d'acide nucléique alternatives et leurs utilisations
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
MY190867A (en) 2015-03-06 2022-05-13 Atea Pharmaceuticals Inc ? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
CN105085357B (zh) * 2015-08-26 2018-04-13 中国科学院化学研究所 小构树碱类化合物及其制备方法和应用
CN105085356B (zh) * 2015-08-26 2018-09-07 中国科学院化学研究所 小构树碱类化合物及其制备方法和应用
WO2017049286A1 (fr) * 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucléotides contenant un lieur morpholino
MX2018010923A (es) 2016-03-10 2019-02-13 Janssen Pharmaceutica Nv Analogos de nucleosidos sustituidos para su uso como inhibidores de prmt5.
EP3500581A4 (fr) 2016-08-17 2021-10-06 Solstice Biologics, Ltd. Constructions polynucléotidiques
EA037868B1 (ru) 2016-09-07 2021-05-28 Атеа Фармасьютикалс, Инк. 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
EP3519413A1 (fr) 2016-10-03 2019-08-07 Janssen Pharmaceutica NV Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5
JP7066728B2 (ja) 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
MY195860A (en) 2017-02-27 2023-02-24 Janssen Pharmaceutica Nv Use of Biomarkers in Identifying Cancer Patients That will be Responsive to Treatment with a Prmt5 Inhibitor
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
CN107973830B (zh) * 2017-11-23 2020-06-05 中国科学院成都生物研究所 一种新奥霉素的全合成方法
EP4385996A2 (fr) 2017-12-08 2024-06-19 JANSSEN Pharmaceutica NV Nouveaux analogues spirobicycliques
CN112351799A (zh) 2018-04-10 2021-02-09 阿堤亚制药公司 具有硬化的hcv感染患者的治疗
WO2020072991A1 (fr) * 2018-10-05 2020-04-09 Ionis Pharmaceuticals, Inc. Composés oligomères modifiés et leurs utilisations
WO2020205867A1 (fr) 2019-04-02 2020-10-08 Aligos Therapeutics, Inc. Composés ciblant prmt5
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
EP4065715A4 (fr) * 2019-11-27 2024-04-10 Alnylam Pharmaceuticals, Inc. Synthèse d'oligonucléotides de 3'-arn
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4323362A1 (fr) 2021-04-16 2024-02-21 Gilead Sciences, Inc. Procédés de préparation de carbanucléosides à l'aide d'amides
CN117836307A (zh) 2021-06-18 2024-04-05 弘景生物科技有限公司 功能化的n-乙酰基半乳糖胺核苷
WO2023034719A1 (fr) 2021-08-30 2023-03-09 Hongene Biotech Corporation Analogues de n-acétylgalactosamine fonctionnalisés
WO2023114746A1 (fr) 2021-12-15 2023-06-22 Hongene Biotech Corporation Analogues de n-acétylgalactosamine fonctionnalisés

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0360626A1 (fr) * 1988-09-20 1990-03-28 Centre National De La Recherche Scientifique (Cnrs) Procédé de synthèse d'oligoribonucléotides alpha et composés utiles dans le procédé
WO1996013512A2 (fr) * 1994-10-24 1996-05-09 Genencor International, Inc. Nucleosides de l-ribofuranosyle
WO1999014226A2 (fr) * 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
WO2000056748A1 (fr) * 1999-03-18 2000-09-28 Exiqon A/S Analogues de xylo-lna
WO2000066604A2 (fr) * 1999-05-04 2000-11-09 Exiqon A/S Analogues de l-ribo-lna
WO2001025248A2 (fr) * 1999-10-04 2001-04-12 Exiqon A/S Conception d'un oligonucleotide de recrutement de rnase h a haute affinite

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0360626A1 (fr) * 1988-09-20 1990-03-28 Centre National De La Recherche Scientifique (Cnrs) Procédé de synthèse d'oligoribonucléotides alpha et composés utiles dans le procédé
WO1996013512A2 (fr) * 1994-10-24 1996-05-09 Genencor International, Inc. Nucleosides de l-ribofuranosyle
WO1999014226A2 (fr) * 1997-09-12 1999-03-25 Exiqon A/S Analogues d'oligonucleotides
WO2000056748A1 (fr) * 1999-03-18 2000-09-28 Exiqon A/S Analogues de xylo-lna
WO2000066604A2 (fr) * 1999-05-04 2000-11-09 Exiqon A/S Analogues de l-ribo-lna
WO2001025248A2 (fr) * 1999-10-04 2001-04-12 Exiqon A/S Conception d'un oligonucleotide de recrutement de rnase h a haute affinite

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA ET BIOPHYSICA ACTA, vol. 157, no. 2, 1968, pages 221 - 232, ISSN: 0006-3002 *
CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 15, no. 12, 1967, pages 2011 - 2014, ISSN: 0009-2363 *
DATABASE STN INTERNATIONAL [online] FILE CAPLUS; DEBART F ET AL: "Synthesis and base-pairing properties of the nuclease-resistant alpha-anomeric dodecarbonucleotide alpha-[r(UCUUAACCCACA)].", XP002902895, retrieved from CAPLUS accession no. 117:27030 Database accession no. 1992:427030 *
DATABASE STN INTERNATIONAL [online] FILE CAPLUS; NISHIMURA TAKUZO ET AL: "Optical rotatory dispersion of the anomeric nucleosides and nucleotides.", XP002902893, retrieved from CAPLUS accession no. 68:114910 Database accession no. 1968:114910 *
DATABASE STN INTERNATIONAL [online] FILE CAPLUS; SECRIST J A ET AL: "Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase.", XP002902894, retrieved from CAPLUS accession no. 131:223117 Database accession no. 1999:448641 *
DATABASE STN INTERNATIONAL [online] FILE CAPLUS; SHIMIZU BUNJI ET AL: "5'-Phosphates of the anomers of 1-L-ribofuranosyluracil, -cytosine, and -thymine. The synthesis of anomeric pyrimidine nucleotides by the trimethylsilyl "fusion" method.", XP002902891, retrieved from CAPLUS accession no. 90:23528 Database accession no. 1979:23528 *
DATABASE STN INTERNATIONAL [online] FILE CAPLUS; SHIMIZU BUNJI ET AL: "Synthesis of anomeric pyrimidine nucleoside 5'-phosphates of L-ribose, alpha-D-cytidine 5'-phosphate, and 3-bêta-L-ribofuranosyladenine 5'-phosphate.", XP002902892, retrieved from CAPLUS accession no. 70:4499 Database accession no. 1969:4499 *
NUCLEIC ACID CHEM, vol. 2, 1978, Wiley New York, pages 783 - 792 *
NUCLEIC ACIDS RESEARCH, vol. 20, no. 6, 1992, pages 1193 - 1200, ISSN: 0305-1048 *
NUCLEOSIDES & NUCLEOTIDES, vol. 18, no. 4 & 5, 1999, pages 745 - 757, ISSN: 0732-8311 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394330B2 (en) 2012-03-21 2016-07-19 Alios Biopharma, Inc. Solid forms of a thiophosphoramidate nucleotide prodrug
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
WO2003039523A2 (fr) 2003-05-15
AU2002351077A1 (en) 2003-05-19

Similar Documents

Publication Publication Date Title
WO2003039523A3 (fr) Oligonucleotides modifies a l'aide de nouveaux analogues d'arn-l-alpha
WO2003020739A3 (fr) Compositions d'acides nucleiques verrouilles et utilisations
EP2258847A3 (fr) Autres nouvelles formes de molécules d'ARN interférant
WO2003002711A3 (fr) NOUVEAU GROUPE D'α-AMYLASES, ET PROCEDE D'IDENTIFICATION ET D'OBTENTION DE NOUVELLES α-AMYLASES
CA2384838A1 (fr) Procedes et compositions utiles pour l'amplification isothermique lineaire de sequences de polynucleotides
WO2004015075A3 (fr) Arn interferant courts possedant une structure en epingle a cheveux contenant une boucle non nucleotidique
WO2006002038A3 (fr) Multimeres d'oligonucleotides immunostimulateurs
WO2003057840A3 (fr) Compositions pour silençage genique regule par adn
WO2007045998A3 (fr) Paires de bases d'acides nucleiques
WO2005120230A3 (fr) Produits de synthese d'arnsi modifies en position
EP3040423A3 (fr) Micro-arn et ses utilisations
WO2007085485A3 (fr) Oligonucléotides phosphorés thiolés modifiés par des acides nucléiques verrouillés
EP2341057A3 (fr) Analogues d'oligonucléotides
WO2005023995A3 (fr) Composes oligomeres chimeriques comprenant des zones alternees a geometrie conformationnelle nord et sud
WO2007112263A3 (fr) Compositions de monomères permettant la synthèse d'arn, procédés de synthèse et procédés de déprotection
EP1445312A4 (fr) Procede pour inhiber l'expression de genes
WO2004046160A3 (fr) Conception antisens
WO2001088173A3 (fr) Procedes d'assemblage enzymatique de polynucleotides et identification de polynucleotides possedant des caracteristiques souhaitees
WO2003052132A3 (fr) Analogues d'oligonucleotides lineaires et en epingle a cheveux comprenant des pseudonucleotides intercalants
WO2002097096A3 (fr) Sequences nucleotidiques codant pour le gene metd
WO2004065600A3 (fr) Interference d'arn par des molecules d'arn palindromiques et marquees
WO2006046076A3 (fr) Applications de fragments d'acide nucleique
WO1996006949A3 (fr) Sondes de detection par hybridation d'acides nucleiques ciblant les acides nucleiques de mycoplasma pneumoniae
AU2001285844A1 (en) Nucleotide sequences which code for the meth gene
WO2002010182A3 (fr) Procedes conçus pour isoler un brin d'un acide nucleique a double brin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002785789

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002785789

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP